Sanofi v. Alembic Pharmaceuticals Limited
1:14-cv-00424
Overview
Parties
Defendant
Alembic Limited NPE (University / Research)
Represented By
0 Attorneys ListedAlembic Pharmaceuticals Limited NPE (University / Research)
Represented By
7 Attorneys ListedADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Plaintiff
Sanofi-Aventis US LLC Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Sanofi Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,323,493 Asserted | Asserted Patent | View Official Patent → |
| π«π· France | FR 9707795 A | France Counterpart | View Official Patent → |
| π«π· France | FR 2764800 B1 | France Counterpart | View Official Patent → |
| π PCT International (WIPO) | WO 1998058643 A1 | PCT World Application | View Official Patent → |
| πΊπΈ United States | US 8,318,800 B2 | US Continuation / Sibling | View Official Patent → |
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7323493
Solid pharmaceutical composition containing benzofuran derivatives
|
Filed: 1998-06-19
Issued: 2008-01-29
|
Expired (Term Ended)
Expires: 2018-06-19
|
|
|
US8318800
Solid pharmaceutical compositions containing benzofuran derivatives
|
Filed: 2007-12-13
Issued: 2012-11-27
|
Expired (Term Ended)
Expires: 2019-06-15
|
|
|
US8410167
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
|
Filed: 2009-04-16
Issued: 2013-04-02
|
Active (2.4 yrs remaining)
Expires: 2029-04-16
|
|
|
US8602215
Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
|
Filed: 2011-06-30
Issued: 2013-12-10
|
Active (4.6 yrs remaining)
Expires: 2031-06-30
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
4
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings